A similar phenomenon is observed in BRAF-mutant melanoma, where co-occurring PTEN loss or NRAS mutations activate alternative signaling pathways, ultimately limiting the efficacy of BRAF inhibitors [27,28]. Here, NRAS is linked to melanoma.